{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:22:00Z","timestamp":1772803320153,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3612,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s13311-013-0217-2","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T11:20:10Z","timestamp":1379503210000},"page":"688-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Treatment of Niemann\u2013Pick Type C Disease by Histone Deacetylase Inhibitors"],"prefix":"10.1016","volume":"10","author":[{"given":"Paul","family":"Helquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick R.","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert L.","family":"Wiech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Wiest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0217-2_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann-Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-013-0217-2_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbamcr.2008.11.014","article-title":"Secondary lipid accumulation in lysosomal disease","volume":"1793","author":"Walkley","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-013-0217-2_bib3","first-page":"1","article-title":"Ein unbekanntes Krankheitsbild","volume":"79","author":"Niemann","year":"1914","journal-title":"Jahrbuch f\u00fcr Kinderheilkunde"},{"key":"10.1007\/s13311-013-0217-2_bib4","first-page":"519","article-title":"Morbus Gaucher und die ihm \u00e4hnlichen Krankheiten (die lipoidzellige Splenohepatomegalie Typus Niemann und die diabetische Lipoidzellenhypoplasie der Milz","volume":"29","author":"Der","year":"1926","journal-title":"Ergebnisse der Inneren Medizin und Kinderheilkunde, Berlin"},{"key":"10.1007\/s13311-013-0217-2_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195802000-00001","article-title":"Niemann\u2013Pick disease: a review of eighteen patients","volume":"37","author":"Crocker","year":"1958","journal-title":"Medicine"},{"key":"10.1007\/s13311-013-0217-2_bib6","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1016\/S0021-9258(18)66632-3","article-title":"Type C Niemann\u2013Pick disease. Abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts","volume":"261","author":"Kruth","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib7","doi-asserted-by":"crossref","first-page":"16775","DOI":"10.1016\/S0021-9258(18)66633-5","article-title":"Type C Niemann\u2013Pick disease. A parallel loss of regulatory responses in both the uptake and esterification of low density lipoprotein-derived cholesterol in cultured fibroblasts","volume":"261","author":"Pentchev","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.277.5323.228","article-title":"Niemann\u2013Pick C1 disease gene: homology to mediators of cholesterol homeostasis","volume":"277","author":"Carstea","year":"1997","journal-title":"Science"},{"key":"10.1007\/s13311-013-0217-2_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-8-35","article-title":"Niemann\u2013Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators","volume":"8","author":"Stampfer","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-013-0217-2_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/13651501.2012.687451","article-title":"Treatable metabolic psychoses that go undetected: What Niemann\u2013Pick type C can teach us","volume":"16","author":"Kluenemann","year":"2010","journal-title":"Int J Psych Clin Pract"},{"key":"10.1007\/s13311-013-0217-2_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddt284","article-title":"Genetic screening for Niemann\u2013Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study","author":"Bauer","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1007\/s13311-013-0217-2_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","article-title":"Linear clinical progression, independent of age of onset, in Niemann\u2013Pick disease, type C","volume":"153B","author":"Yanjanin","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1007\/s13311-013-0217-2_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/jnnp.2005.086785","article-title":"Niemann\u2013Pick type C disease in a 68-year-old patient","volume":"77","author":"Trendelenburg","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0217-2_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10072-012-1155-1","article-title":"Vertical supranuclear gaze palsy in Niemann\u2013Pick type C disease","volume":"33","author":"Salsano","year":"2012","journal-title":"Neur Sci."},{"key":"10.1007\/s13311-013-0217-2_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbalip.2004.08.011","article-title":"Consequences of NPC1 and NPC2 loss of function in mammalian neurons","volume":"1685","author":"Walkley","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-013-0217-2_bib16","doi-asserted-by":"crossref","first-page":"36710","DOI":"10.1074\/jbc.M608743200","article-title":"NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols","volume":"281","author":"Liou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1074\/jbc.M707943200","article-title":"Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein","volume":"283","author":"Infante","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cell.2009.03.049","article-title":"Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol","volume":"137","author":"Kwon","year":"2009","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0217-2_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cmet.2010.05.016","article-title":"Identification of surface residues on Niemann\u2013Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes","volume":"12","author":"Wang","year":"2010","journal-title":"Cell Metab"},{"key":"10.1007\/s13311-013-0217-2_bib20","doi-asserted-by":"crossref","first-page":"23525","DOI":"10.1074\/jbc.M703848200","article-title":"Structural basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann\u2013Pick type C2 disease","volume":"282","author":"Xu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib21","doi-asserted-by":"crossref","first-page":"18932","DOI":"10.1073\/pnas.1110439108","article-title":"Niemann\u2013Pick type C 1 function requires lumenal domain residues that mediate cholesterol-dependent NPC2 binding","volume":"108","author":"Deffieu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/10084","article-title":"Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport","volume":"1","author":"Kobayashi","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-013-0217-2_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bbalip.2009.03.002","article-title":"Intracellular sterol dynamics","volume":"1791","author":"Mesmin","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-013-0217-2_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1600-0854.2010.01046.x","article-title":"Improvement in lipid and protein trafficking in Niemann\u2013Pick C1 cells by correction of a secondary enzyme defect","volume":"11","author":"Devlin","year":"2011","journal-title":"Traffic"},{"key":"10.1007\/s13311-013-0217-2_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann\u2013Pick disease type C: long-term data from a clinical trial","volume":"99","author":"Wraith","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-013-0217-2_bib26","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1074\/jbc.M708735200","article-title":"Niemann\u2013Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding","volume":"283","author":"Gelsthorpe","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dof.2009.34.4.1352412","article-title":"Current status of drug therapy development for Niemann\u2013Pick type C disease","volume":"34","author":"Helquist","year":"2009","journal-title":"Drugs Future"},{"key":"10.1007\/s13311-013-0217-2_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1212\/WNL.43.1_Part_1.61","article-title":"The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann\u2013Pick disease type C","volume":"43","author":"Patterson","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0217-2_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0887-8994(94)90028-0","article-title":"Magnetic resonance spectroscopy in Niemann\u2013Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin","volume":"10","author":"Sylvain","year":"1994","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-013-0217-2_bib30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbrc.2004.01.066","article-title":"Chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons","volume":"315","author":"Cheung","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-013-0217-2_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jneumeth.2007.09.002","article-title":"Partial blockage of sterol biosynthesis with a squalene synthase inhibitor in early postnatal Niemann\u2013Pick type C npcnih null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation","volume":"168","author":"Reid","year":"2008","journal-title":"J Neurosci Methods"},{"key":"10.1007\/s13311-013-0217-2_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1194\/jlr.M600488-JLR200","article-title":"Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann\u2013Pick type C disease","volume":"48","author":"Beltroy","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-013-0217-2_bib33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0006-2952(98)00234-2","article-title":"Reduced cholesterol accumulation and improved deficient peroxisomal functions in a murine model of Niemann\u2013Pick type C disease upon treatment with peroxisomal proliferators","volume":"56","author":"Schedin","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1007\/s13311-013-0217-2_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0009-8981(03)00341-3","article-title":"Effect of a peroxysomal proliferator agent on intracellular cholesterol accumulation in cultured fibroblasts from Niemann\u2013Pick type C disease patients","volume":"336","author":"Beheregaray","year":"2003","journal-title":"Clin Chim Acta"},{"key":"10.1007\/s13311-013-0217-2_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nm1073","article-title":"Niemann\u2013Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone","volume":"10","author":"Griffin","year":"2004","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0217-2_bib36","doi-asserted-by":"crossref","first-page":"13807","DOI":"10.1073\/pnas.0606218103","article-title":"Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann\u2013Pick C disease","volume":"103","author":"Langmade","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib37","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1074\/jbc.M000875200","article-title":"Cholesterol movement in Niemann\u2013Pick type C cells and in cells treated with amphiphiles","volume":"275","author":"Lange","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib38","doi-asserted-by":"crossref","first-page":"25517","DOI":"10.1074\/jbc.M302588200","article-title":"NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols","volume":"278","author":"Frolov","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/glia.20563","article-title":"Decreased estradiol release from astrocytes contributes to the neurodegeneration in a mouse model of Niemann\u2013Pick disease type C","volume":"55","author":"Chen","year":"2007","journal-title":"Glia"},{"key":"10.1007\/s13311-013-0217-2_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tcm.2003.12.003","article-title":"The Niemann\u2013Pick disease genes; regulators of cellular cholesterol homeostasis","volume":"14","author":"Ory","year":"2004","journal-title":"Trends Cardiovasc Med"},{"key":"10.1007\/s13311-013-0217-2_bib41","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.1523\/JNEUROSCI.4823-07.2007","article-title":"Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse","volume":"27","author":"Repa","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0217-2_bib42","doi-asserted-by":"crossref","first-page":"37081","DOI":"10.1074\/jbc.M606890200","article-title":"Correction of apolipoprotein A-I-mediated lipid efflux and high density lipoprotein particle formation in human Niemann\u2013Pick type C disease fibroblasts","volume":"281","author":"Boadu","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib43","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/01.ATV.0000248101.93488.84","article-title":"The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia","volume":"26","author":"Lalloyer","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1007\/s13311-013-0217-2_bib44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann\u2013Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0217-2_bib45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","article-title":"Critical role for glycosphingolipids in Niemann\u2013Pick disease type C","volume":"11","author":"Zervas","year":"2001","journal-title":"Curr Biol"},{"key":"10.1007\/s13311-013-0217-2_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbalip.2004.08.013","article-title":"Therapy of Niemann\u2013Pick disease, type C","volume":"1685","author":"Patterson","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-013-0217-2_bib47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann\u2013Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0217-2_bib48","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1002\/cncr.25414","article-title":"Development of curcumin as an epigenetic agent","volume":"116","author":"Fu","year":"2010","journal-title":"Cancer"},{"key":"10.1007\/s13311-013-0217-2_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pbb.2011.12.009","article-title":"Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann\u2013Pick C1","volume":"101","author":"Borbon","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-013-0217-2_bib50","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1096\/fj.07-102715","article-title":"Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann\u2013Pick type C disease","volume":"22","author":"Alvarez","year":"2008","journal-title":"FASEB J"},{"key":"10.1007\/s13311-013-0217-2_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jnr.10257","article-title":"Studies on neuronal death in the mouse model of Niemann\u2013Pick C disease","volume":"68","author":"Erickson","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-013-0217-2_bib52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/cr.2008.48","article-title":"Impaired functions of neural stem cells by abnormal nitric oxide-mediated signaling in an in vitro model of Niemann\u2013Pick type C disease","volume":"18","author":"Kim","year":"2008","journal-title":"Cell Res"},{"key":"10.1007\/s13311-013-0217-2_bib53","first-page":"461","article-title":"Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann\u2013Pick C","volume":"45","author":"Bascunan-Castillo","year":"2004","journal-title":"J Appl Genet"},{"key":"10.1007\/s13311-013-0217-2_bib54","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1194\/jlr.M015560","article-title":"Altered vitamin E status in Niemann\u2013Pick type C disease","volume":"52","author":"Ulatowski","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-013-0217-2_bib55","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1194\/jlr.M200179-JLR200","article-title":"Identification of a pharmaceutical compound that partially corrects the Niemann\u2013Pick C phenotype in cultured cells","volume":"43","author":"Liscum","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-013-0217-2_bib56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1194\/jlr.M500388-JLR200","article-title":"Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann\u2013Pick C cells","volume":"47","author":"Pipalia","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-013-0217-2_bib57","doi-asserted-by":"crossref","first-page":"e12788","DOI":"10.1371\/journal.pone.0012788","article-title":"Cholesterol pathways affected by small molecules that decrease sterol levels in Niemann\u2013Pick type C mutant cells","volume":"5","author":"Rujoi","year":"2010","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0217-2_bib58","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1021\/jm900707n","article-title":"Investigation of N-aryl-3-alkylidenepyrrolinones as potential Niemann-Pick type C disease therapeutics","volume":"52","author":"Cosner","year":"2009","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-013-0217-2_bib59","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1021\/jm100499s","article-title":"Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann\u2013Pick type C disease therapeutics","volume":"53","author":"Rosenbaum","year":"2010","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-013-0217-2_bib60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1010588112003","article-title":"Effects of dietary cholesterol restriction in a feline model of Niemann\u2013Pick type C disease","volume":"24","author":"Somers","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-013-0217-2_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1750-1172-7-76","article-title":"Dysphagia as a risk factor for mortality in Niemann\u2013Pick disease type C: systematic literature review and evidence from studies with miglustat","volume":"7","author":"Walterfang","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-013-0217-2_bib62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1007\/s13311-013-0217-2_bib63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","article-title":"Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann\u2013Pick type C1 mouse and markedly prolongs life","volume":"68","author":"Ramirez","year":"2010","journal-title":"Pediatr Res"},{"key":"10.1007\/s13311-013-0217-2_bib64","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M040618","article-title":"Identification of Niemann\u2013Pick C1 (NPC1) disease biomarkers through sphingolipid profiling","author":"Fan","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-013-0217-2_bib66","doi-asserted-by":"crossref","first-page":"e53280","DOI":"10.1371\/journal.pone.0053280","article-title":"Hearing loss and hair cell death in mice given the cholesterol-chelating agent hydroxypropyl-beta-cyclodextrin","volume":"7","author":"Crumling","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0217-2_bib67","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann\u2013Pick type C1 mutant human fibroblasts","volume":"108","author":"Pipalia","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib68","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbrc.2007.06.116","article-title":"Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann\u2013Pick type C disease improved by valproic acid, a histone deacetylase inhibitor","volume":"360","author":"Kim","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1007\/s13311-013-0217-2_bib70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bbrc.2008.11.103","article-title":"Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors","volume":"378","author":"Shafaati","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-013-0217-2_bib71","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-013-0226-1","article-title":"Small Molecule Inhibitors of Zinc-Dependent Histone Deacetylases (HDACs)","author":"Wagner","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-013-0217-2_bib72","unstructured":"Pipalia NH, Maxfield FR. Investigating the therapeutic potential of HDAC Inhibitors for the treatment of Niemann Pick type C1 Disease. Mol Biol Cell 2011;22:abstract #1642."},{"key":"10.1007\/s13311-013-0217-2_bib73","doi-asserted-by":"crossref","first-page":"23842","DOI":"10.1074\/jbc.M111.227645","article-title":"An \u201cexacerbate-reverse\u201d strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann\u2013Pick type C disease","volume":"286","author":"Munkacsi","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib74","doi-asserted-by":"crossref","first-page":"e48561","DOI":"10.1371\/journal.pone.0048561","article-title":"Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann\u2013Pick type C fibroblasts","volume":"7","author":"Wehrmann","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1007\/s13311-013-0217-2_bib75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0217-2_bib76","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","article-title":"The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells","volume":"162","author":"Tiffon","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-013-0217-2_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/156802609788085241","article-title":"Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders","volume":"9","author":"Wiech","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1007\/s13311-013-0217-2_bib78","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3945\/ajcn.110.009043","article-title":"Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients","volume":"93","author":"Marini","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"1 Suppl.","key":"10.1007\/s13311-013-0217-2_bib79","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1067\/mpd.2001.111836","article-title":"Alternative pathway therapy for urea cycle disorders: twenty years later","volume":"138","author":"Batshaw","year":"2001","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-013-0217-2_bib80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V85.1.43.bloodjournal85143","article-title":"Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial","volume":"85","author":"Collins","year":"1995","journal-title":"Blood"},{"key":"10.1007\/s13311-013-0217-2_bib81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","article-title":"Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate","volume":"8","author":"Dover","year":"1994","journal-title":"Blood"},{"key":"10.1007\/s13311-013-0217-2_bib82","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI119788","article-title":"In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR","volume":"100","author":"Rubenstein","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-013-0217-2_bib83","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jpeds.2012.11.084","article-title":"Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate","volume":"162","author":"Smith","year":"2013","journal-title":"J Pediatr."},{"key":"10.1007\/s13311-013-0217-2_bib84","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-013-0217-2_bib85","article-title":"Epigenetic drugs in cognitive disorders","author":"Peedicayil","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-013-0217-2_bib86","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-pharmtox-011112-140216","article-title":"The potential of HDAC inhibitors as cognitive enhancers","volume":"53","author":"Graff","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-013-0217-2_bib87","doi-asserted-by":"crossref","first-page":"40545","DOI":"10.1074\/jbc.M402229200","article-title":"Regulation of histone acetylation during memory formation in the hippocampus","volume":"279","author":"Levenson","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0217-2_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nlm.2011.04.002","article-title":"The role of histone acetylation in age-associated memory impairment and Alzheimer's disease","volume":"96","author":"Stilling","year":"2011","journal-title":"Neurobiol Learn Mem"},{"key":"10.1007\/s13311-013-0217-2_bib89","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-013-0217-2_bib90","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-013-0217-2_bib91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-013-0217-2_bib92","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jchromb.2006.04.044","article-title":"A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum","volume":"840","author":"Parise","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1007\/s13311-013-0217-2_bib93","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-013-2220-z","article-title":"Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor","volume":"72","author":"Iwamoto","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1007\/s13311-013-0217-2_bib94","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/hmg\/ddr505","article-title":"A novel mouse model of Niemann\u2013Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations","volume":"21","author":"Maue","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0217-2_bib95","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/NEN.0b013e318286587f","article-title":"Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of Niemann\u2013Pick disease type C","volume":"72","author":"Bagel","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-013-0217-2_bib96","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-013-0217-2_bib97","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","article-title":"Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks","volume":"15","author":"Palmieri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-013-0217-2_bib98","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature07925","article-title":"HDAC2 negatively regulates memory formation and synaptic plasticity","volume":"459","author":"Guan","year":"2009","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0217-2_bib100","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-013-0217-2_bib101","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0217-2_bib102","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0217-2_bib103","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-013-0217-2_bib104","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/pbc.24541","article-title":"A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study","volume":"60","author":"Hummel","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-013-0217-2_bib105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-013-0217-2_bib106","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0032-1323692","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia","volume":"224","author":"Witt","year":"2012","journal-title":"Klin Padiatr"},{"key":"10.1007\/s13311-013-0217-2_bib107","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"10.1007\/s13311-013-0217-2_bib108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1007\/s13311-013-0217-2_bib109","first-page":"994","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate","volume":"6","author":"Riva","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-013-0217-2_bib110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuropharm.2012.06.043","article-title":"Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity","volume":"64","author":"Fass","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-013-0217-2_bib111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neulet.2013.06.016","article-title":"FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors","volume":"550","author":"Schroeder","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-013-0217-2_bib112","doi-asserted-by":"crossref","DOI":"10.4161\/epi.25202","article-title":"Class I HDAC imaging using [ ( 3) H]CI-994 autoradiography","author":"Wang","year":"2013","journal-title":"Epigenetics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0217-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301663X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301663X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0217-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:36Z","timestamp":1761808056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301663X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S187874792301663X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0217-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Niemann\u2013Pick Type C Disease by Histone Deacetylase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0217-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}